iBet uBet web content aggregator. Adding the entire web to your favor.
iBet uBet web content aggregator. Adding the entire web to your favor.



Link to original content: https://pubmed.ncbi.nlm.nih.gov/21993207/
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Feb;37(3):697-706.
doi: 10.1038/npp.2011.247. Epub 2011 Oct 12.

Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression

Michael F Grunebaum  1 , Steven P Ellis, Naihua Duan, Ainsley K Burke, Maria A Oquendo, J John Mann
Affiliations
Randomized Controlled Trial

Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression

Michael F Grunebaum et al. Neuropsychopharmacology. 2012 Feb.

Abstract

Randomized controlled trials in depressed patients selected for elevated suicidal risk are rare. The resultant lack of data leaves uncertainty about treatment in this population. This study compared a serotonin reuptake inhibitor with a noradrenergic/dopaminergic antidepressant in major depression with elevated suicidal risk factors. We conducted a double-blind, randomized, clinical pilot trial of paroxetine (N=36) or bupropion (N=38) in DSM IV major depression with a suicide attempt history or current suicidal ideation. The effects during acute (8 weeks) and continuation treatment (up to 16 weeks) were measured. Main outcomes were suicidal behavior and ideation. The secondary outcome was modified 17-item Hamilton Depression Rating Scale score subtracting the suicide item (mHDRS-17). Treatment was not associated with time to a suicidal event and no treatment main effect or treatment × time interaction on suicidal ideation or mHDRS-17 was found. Exploratory model selection showed modest advantages for paroxetine on: (1) mHDRS-17 (p=0.02); and (2) in a separate model adjusted for baseline depression, for suicidal ideation measured with the Beck Scale for Suicidal Ideation (p=0.03), with benefit increasing with baseline severity. Depressed patients with greater baseline suicidal ideation treated with paroxetine compared with bupropion appeared to experience greater acute improvement in suicidal ideation, after adjusting for global depression. Given the lack of evidence-based pharmacotherapy guidelines for suicidal, depressed patients-an important public health population-this preliminary finding merits further study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of progress through phases of the parallel randomized trial of two groups (enrollment, intervention allocation, follow-up, and data analysis) (Schulz et al, 2010).
Figure 2
Figure 2
Scatter-plot of Scale for Suicidal Ideation (SSI) (Beck et al, 1979) score vs time, by treatment, in patients with baseline SSI ⩽8. Locally weighted polynomial regression lines for scatter-plot smoothing (Cleveland, 1979) use 80% of points to fit and Epanechnikov kernel. Data points may represent more than one patient.
Figure 3
Figure 3
Scatter-plot of Scale for Suicidal Ideation (SSI) (Beck et al, 1979) score vs time, by treatment, in patients with baseline SSI ⩾9. Locally weighted polynomial regression lines for scatter-plot smoothing (Cleveland, 1979) use 80% of points to fit and Epanechnikov kernel. Data points may represent more than one patient.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baldessarini RJ.2006Drug therapy of depression and anxiety disordersIn: Brunton LL, Lazo JS, Parker KL (eds).Goodman and Gilman's The Pharmacological Basis of Therapeutics McGraw-Hill: New York; 429–459.
    1. Beck AT, Brown GK, Steer RA, Dahlsgaard KK, Grisham JR. Suicide ideation at its worst point: a predictor of eventual suicide in psychiatric outpatients. Suicide Life Threat Behav. 1999;29:1–9. - PubMed
    1. Beck AT, Kovacs M, Weissman A. Assessment of suicidal intention: the scale for suicide ideation. J Consult Clin Psychol. 1979;47:343–352. - PubMed
    1. Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M. Prescription sleeping pills, insomnia, and suicidality in the National Comorbidity Survey Replication. J Clin Psychiatry. 2011;72:515–521. - PubMed
    1. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in human correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979;1:131–139. - PubMed

Publication types

MeSH terms